Topical therapies for impetigo

Pediatric Emergency Care

Volumn 26, Issue 3, 2010, Pages 222-231

  Feaster, Tasha ^a   Singer, Jonathan I ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Impetigo; Pyoderma; Topical therapy

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; NEOMYCIN; PLACEBO; POLYMYXIN B; PSEUDOMONIC ACID; RETAPAMULIN; TEA TREE OIL;

BACTERIAL VIRULENCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DIARRHEA; DRUG COST; DRUG EFFICACY; ECTHYMA; ECZEMA; FEVER; HEADACHE; HUMAN; IMPETIGO; IMPETIGO BULLOSA; NEPHROTOXICITY; OTOTOXICITY; PAIN; PATHOGENESIS; PRURITUS; REVIEW; RHINOPHARYNGITIS; SKIN ALLERGY; SKIN IRRITATION; TOPICAL TREATMENT; TREATMENT OUTCOME; URTICARIA;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; HUMANS; IMPETIGO;

EID: 77949347308     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e3181d1e71b     Document Type: Review

References (45)

1. Dillon HC Jr. Impetigo contagiosa: suppurative and non-suppurative complications. I. Clinical, bacteriologic, and epidemiologic characteristics of impetigo. Am J Dis Child. 1968;115:530-541.
2. Hayden GF. Skin diseases encountered in a pediatric clinic. A one-year prospective study. Am J Dis Child. 1985;139:36-38.
3. Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51:291-298.
4. Lookingbill DP. Impetigo. Pediatrics in Review. 1985;7:177-181.
5. Luby SP, Agboatwalla M, Feikin DR, et al. Effect of handwashing on child health: a randomised controlled trial. Lancet. 2005;366:225-233.
6. Tunnessen WW Jr. Cutaneous infections. Pediatr Clin North Am. 1983;30:515-532.
7. Blumer JL, Lemon E, O'Horo J, et al. Changing therapy for skin and soft tissue infections in children: have we come full circle? Pediatr Infect Dis J. 1987;6:117-122.
8. Peter G, Smith AL. Group A streptococcal infections of the skin and pharynx (first of two parts). N Engl J Med. 1977;297:311-317.
9. Dagan R. Impetigo in childhood: changing epidemiology and new treatments. Pediatr Ann. 1993;22:235-240.
10. Wannamaker LW. Differences between streptococcal infections of the throat and of the skin (second of two parts). N Engl J Med. 1970;282:78-85.
11. Baltimore RS. Treatment of impetigo: a review. Pediatr Infect Dis. 1985;4:597-601.
12. Lin JJ, Wu CT, Hsia SH, et al. Bullous impetigo: a rare presentation in fulminant streptococcal toxic shock syndrome. Pediatr Emerg Care. 2007;23:318-320.
13. Stewart C. Skin and soft tissue infection update: presentation, diagnosis and syndrome-specific antibiotic management. Emerg Med Rep. 2000;21:35-44.
14. Ben-Amitai D, Ashkenazi S. Common bacterial skin infections in childhood. Pediatr Ann. 1993;22:225-227, 231-233.
15. Shriner DL, Schwartz RA, Janniger CK. Impetigo. Cutis. 1995;56:30-32.
16. Wallin TR, Hern HG, Frazee BW. Community-associated methicillin-resistant Staphylococcus aureus. Emerg Med Clin North Am. 2008;26:431-455, ix.
17. Hans D, Kelly E, Wilhelmson K, et al. Rapidly fatal infections. Emerg Med Clin North Am. 2008;26:259-279, vii.
18. Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J. 2008;27:1-7.
19. Dillon HC Jr. Topical and systemic therapy for pyodermas. Int J Dermatol. 1980;19:443-451.
20. Darmstadt GL. Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Pediatr Infect Dis J. 1997;16:227-240.
21. Leyden JJ. Review of mupirocin ointment in the treatment of impetigo. Clin Pediatr (Phila). 1992;31:549-553.
22. Rice TD, Duggan AK, DeAngelis C. Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. Pediatrics. 1992;89:210-214.
23. Eells LD, Mertz PM, Piovanetti Y, et al. Topical antibiotic treatment of impetigo with mupirocin. Arch Dermatol. 1986;122:1273-1276.
24. Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila). 2008;47:211-219.
25. Mertz PM, Marshall DA, Eaglstein WH, et al. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol. 1989;125:1069-1073.
26. McLinn S. Topical mupirocin vs. systemic erythromycin treatment for pyoderma. Pediatr Infect Dis J. 1988;7:785-790.
27. Britton JW, Fajardo JE, Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr. 1990;117: 827-829.
28. Ward A, Campoli-Richards DM. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1986;32:425-444.
29. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother. 1998;41:11-18.
30. Gelmetti C. Local antibiotics in dermatology. Dermatol Ther. 2008;21:187-195.
31. Buck M. Retapamulin: a new option for impetigo. Pediatr Pharmacol. 2007;13:1-4.
32. Oranje AP, van der Wouden J, Konig S. Retapamulin ointment for the treatment of impetigo in adults and children: results of a phase III, placebo-controlled, double-blind trial. J Am Acad Dermatol. 2006;5:224-232.
33. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215:331-340.
34. Koning S, van Suijlekom-Smit LW, Nouwen JL, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. Bmj. 2002;324:203-206.
35. Millikan L. Drug Therapy in Dermatology. New York, NY: Marcel Dekker, Inc; 2000:47-54.
36. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53:480-487.
37. Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J. 1997;16:708-710.
38. Katz BE, Fisher AA. Bacitracin: a unique topical antibiotic sensitizer. J Am Acad Dermatol. 1987;17:1016-1024.
39. Graham DR, Correa-Villasenor A, Anderson RL, et al. Epidemic neonatal gentamicin-methicillinYresistant Staphylococcus aureus infection associated with nonspecific topical use of gentamicin. J Pediatr. 1980;97:972-978.
40. Wilkinson RD, Carey WD. Topical mupirocin versus topical neosporin in the treatment of cutaneous infections. Int J Dermatol. 1988;27:514-515.
41. Howard R. The appropriate use of topical antimicrobials and antiseptics in children. Pediatr Ann. 2001;30:219-224.
42. Maddox JS, Ware JC, Dillon HC Jr. The natural history of streptococcal skin infection: prevention with topical antibiotics. J Am Acad Dermatol. 1985;13:207-212.
43. Gardiner P, Coles D, Kemper KJ. The skinny on herbal remedies for dermatologic disorders. Contemp Pediatr. 2001;18:103-114.
44. Carson CF, Riley TV, Cookson BD. Efficacy and safety of tea tree oil as a topical antimicrobial agent. J Hosp Infect. 1998;40:175-178.
45. Martin KW, Ernst E. Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. J Antimicrob Chemother. 2003;51:241-246.